TITLE:
Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients

CONDITION:
Kidney Transplantation

INTERVENTION:
Tacrolimus Modified Release (MR)

SUMMARY:

      The purpose of this study is to compare the safety and efficacy of tacrolimus/mycophenolate
      mofetil (MMF), cyclosporine/MMF and tacrolimus modified release/MMF in de novo kidney
      transplant recipients.
    

DETAILED DESCRIPTION:

      This was a 3 arm randomized, open-label, comparative, multi-center study in de novo kidney
      transplant recipients at 60 centers in the U.S., Canada and Brazil.

      The study consisted of a 1-year post-transplant efficacy and safety study with a clinical
      continuation phase of a minimum of 2 years or until commercial availability of tacrolimus
      modified release, unless the Data Safety Monitoring Board or sponsor specified otherwise.
    

ELIGIBILITY:
Gender: All
Age: 12 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Recipient of a primary or retransplanted non-human leukocyte antigen (HLA)-identical
             living or non-HLA-identical cadaveric kidney transplant

          -  Age greater or equal to 12 years

        Exclusion Criteria:

          -  Recipient or donor is known seropositive for human immunodeficiency virus (HIV)

          -  Has current malignancy or history of malignancy

          -  Has significant liver disease

          -  Has uncontrolled concomitant infection or any other unstable medical condition

          -  Is receiving everolimus or enteric coated mycophenolic acid at any time during the
             study

          -  Received kidney with a cold ischemia time of equal or more than 36 hours

          -  Received kidney transplant from a cadaveric donor equal or more than 60 years of age

          -  Received intravenous immunoglobulin (IVIG) therapy prior to randomization
      
